NewLink Genetics Corporation (NASDAQ:NLNK) is scheduled to post its quarterly earnings results before the market opens on Thursday, November 2nd. Analysts expect NewLink Genetics Corporation to post earnings of ($0.76) per share for the quarter.

NewLink Genetics Corporation (NASDAQ:NLNK) last released its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. The company had revenue of $10.37 million during the quarter, compared to analysts’ expectations of $2.65 million. On average, analysts expect NewLink Genetics Corporation to post $-2.73 EPS for the current fiscal year and $-2.44 EPS for the next fiscal year.

NewLink Genetics Corporation (NASDAQ:NLNK) opened at 9.40 on Thursday. The company’s market cap is $276.56 million. NewLink Genetics Corporation has a 1-year low of $5.90 and a 1-year high of $25.17. The stock has a 50 day moving average price of $11.27 and a 200 day moving average price of $10.78.

In related news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of the firm’s stock in a transaction that occurred on Friday, October 6th. The stock was acquired at an average cost of $10.25 per share, with a total value of $7,999,991.75. Following the completion of the purchase, the insider now directly owns 7,857,732 shares in the company, valued at $80,541,753. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 13.70% of the stock is owned by insiders.

An institutional investor recently raised its position in NewLink Genetics Corporation stock. The Manufacturers Life Insurance Company boosted its holdings in shares of NewLink Genetics Corporation (NASDAQ:NLNK) by 3.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,069 shares of the biotechnology company’s stock after acquiring an additional 556 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.06% of NewLink Genetics Corporation worth $140,000 as of its most recent filing with the Securities and Exchange Commission. 55.18% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/26/newlink-genetics-corporation-nlnk-set-to-announce-earnings-on-thursday.html.

NLNK has been the subject of several research reports. Jefferies Group LLC raised NewLink Genetics Corporation from a “hold” rating to a “buy” rating and lifted their target price for the company from $7.00 to $26.00 in a research note on Friday, September 8th. Stifel Nicolaus lifted their target price on NewLink Genetics Corporation from $14.00 to $29.00 and gave the company a “buy” rating in a research note on Monday, September 11th. Cantor Fitzgerald reissued a “buy” rating and issued a $26.00 target price on shares of NewLink Genetics Corporation in a research note on Friday, September 8th. Bank of America Corporation initiated coverage on NewLink Genetics Corporation in a research note on Friday, October 13th. They issued a “buy” rating and a $22.00 target price for the company. Finally, Zacks Investment Research raised NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a research note on Saturday, July 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $25.83.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Earnings History for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.